SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) — ViroMissile, Inc., a cancer immunotherapy company pioneering the IDOV™ (Intravenously Deliverable Oncolytic Virus) platform, today announced the completion of the first dose cohort in its ongoing first-in-human Phase I trial of IDOV-2 (formerly, IDOV-Immune) in patients with advanced solid tumors (NCT06910657). Following its review of safety data from this cohort, the trial’s independent Safety Review Committee (SRC) cleared the study to proceed to the next, higher dose cohort. The trial is being conducted in the United States, as well as in Australia through ViroMissile’s subsidiary, ViroMissile Australia, PTY, LTD.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
